AbCellera Biologics Inc. (NASDAQ:ABCL – Get Rating) has been assigned a consensus recommendation of "Buy" from the six brokerages that are currently covering the stock, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $28.67.
Several research firms have weighed in on ABCL. The Goldman Sachs Group began coverage on shares of AbCellera Biologics in a research report on Thursday, December 15th. They set a "buy" rating and a $30.00 target price on the stock. Truist Financial began coverage on shares of AbCellera Biologics in a research report on Wednesday, November 16th. They set a "buy" rating and a $29.00 target price on the stock. Piper Sandler dropped their target price on shares of AbCellera Biologics from $22.00 to $21.00 in a research report on Tuesday, November 1st. Finally, SVB Leerink dropped their target price on shares of AbCellera Biologics from $20.00 to $18.00 and set an "outperform" rating on the stock in a research report on Friday, January 6th.
Get AbCellera Biologics alerts:Insider Buying and Selling at AbCellera Biologics
In related news, major shareholder Holdings Ltd. Thermopylae acquired 85,102 shares of AbCellera Biologics stock in a transaction on Friday, December 16th. The stock was acquired at an average price of $10.10 per share, for a total transaction of $859,530.20. Following the purchase, the insider now owns 55,859,493 shares of the company's stock, valued at approximately $564,180,879.30. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 30.30% of the company's stock.
Hedge Funds Weigh In On AbCellera Biologics
Several institutional investors and hedge funds have recently modified their holdings of ABCL. Advisor Group Holdings Inc. increased its stake in shares of AbCellera Biologics by 51.7% in the 1st quarter. Advisor Group Holdings Inc. now owns 40,699 shares of the company's stock valued at $397,000 after purchasing an additional 13,877 shares in the last quarter. JPMorgan Chase & Co. increased its stake in AbCellera Biologics by 83.9% during the 1st quarter. JPMorgan Chase & Co. now owns 150,882 shares of the company's stock worth $1,471,000 after buying an additional 68,844 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in AbCellera Biologics during the 1st quarter worth approximately $283,000. BlackRock Inc. increased its stake in AbCellera Biologics by 3.4% during the 1st quarter. BlackRock Inc. now owns 2,447,299 shares of the company's stock worth $23,861,000 after buying an additional 80,057 shares in the last quarter. Finally, Federated Hermes Inc. increased its stake in AbCellera Biologics by 55.6% during the 1st quarter. Federated Hermes Inc. now owns 1,288,000 shares of the company's stock worth $12,558,000 after buying an additional 460,153 shares in the last quarter. Hedge funds and other institutional investors own 42.19% of the company's stock.AbCellera Biologics Stock Up 1.5 %
NASDAQ ABCL opened at $11.18 on Monday. The firm has a market cap of $3.20 billion, a PE ratio of 14.15 and a beta of -0.16. The company has a 50 day moving average price of $10.59 and a 200 day moving average price of $11.11. AbCellera Biologics has a 52 week low of $5.42 and a 52 week high of $14.97.
AbCellera Biologics (NASDAQ:ABCL – Get Rating) last released its earnings results on Tuesday, November 8th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). The company had revenue of $101.38 million for the quarter, compared to analysts' expectations of $77.19 million. AbCellera Biologics had a return on equity of 21.15% and a net margin of 41.17%. On average, equities research analysts anticipate that AbCellera Biologics will post 0.62 earnings per share for the current fiscal year.
About AbCellera Biologics
(Get Rating)
AbCellera Biologics Inc develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners.
Further Reading
- Get a free copy of the StockNews.com research report on AbCellera Biologics (ABCL)
- Is C3.ai Artificial Intelligence Product Suite a Gamechanger?
- MarketBeat Week in Review – 1/30 – 2/3
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.